PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100

In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgery Shots: The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…

BySenior EditorFebruary 16, 2022

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

BySenior EditorMarch 11, 2021

PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Contact US

OUR INFORMATION

FOLLOW US